CVRx Inc(CVRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.97 | Insider Own | 39.19% | Shs Outstand | 26.6M | Perf Week | -0.7% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 3.89% | Insider Trans | 0.24% | Shs Float | 16.2M | Perf Month | -7.84% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.5 | Inst Own | 31.45% | Short Float | 13.19% | Perf Quarter | -74.36% |
| Income | -0.05B | P/S | 0.61 | EPS this Y | 1.38% | Inst Trans | 3.11% | Short Ratio | 2.25 | Perf Half Y | -82.31% |
| Sales | 0.06B | P/B | 1.88 | EPS next 5Y | 5.35% | ROA | -49.06% | Short Interest | 2.14M | Perf YTD | -80.14% |
| Book/sh | 0.75 | P/C | 0.58 | EPS past 3/5Y | -0.43% -22.44% | ROE | -133.44% | 52W High | -87.52% ($11.30) | Perf Year | -86.75% |
| Cash/sh | 2.42 | P/FCF | - | Sales past 3/5Y | 36.11% 56.4% | ROIC | -65.81% | 52W Low | 12.35% ($1.25) | Perf 3Y | -89.07% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 6.12% | Gross Margin | 85.62% | Volatility(W/M) | 9.08% 8.85% | Perf 5Y | -91.66% |
| Dividend TTM | - | EV/Sales | 0.53 | Sales Y/Y TTM | 11.96% | Oper. Margin | -79.49% | ATR (14) | 0.16 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.87 | EPS Q/Q | 6.3% | Profit Margin | -84.93% | RSI (14) | 32.04 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.04 | Sales Q/Q | 15.57% | SMA20 | -2.69% ($1.45) | Beta | 0.78 | Target Price | $4.3 |
| Payout | - | Debt/Eq | 2.98 | Earnings | 2026/11/5 | SMA50 | -37.69% ($2.26) | Rel Volume | 0.29 | Prev Close | $1.42 |
| Employees | 223 | LT Debt/Eq | 2.96 | EPS/Sales Surpr. | -1.03% 1% | SMA200 | -73.32% ($5.28) | Avg Volume(3M) | 0.95M | Price | $1.41 |
| IPO | 2021/6/30 | Option/Short | Yes/Yes | Trades | 1761 | Volume | 272,766 | Change | -1.05% |
🫀 A medical device company headquartered in Minnesota, USA, that develops and supplies minimally invasive implantable neurostimulators for heart failure treatment. With its flagship Barostim system being the only device approved in the field of baroreflex activation therapy, the company holds a specialized market position as a niche medical device firm, supplying its products to cardiologists and hospitals.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 29% of its average volume.
Next earnings report: November 5
3 days to go.
CVRX has a sound balance sheet but weak earning power
Of every $100 in sales, $79.49 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +1.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $61. Peers typically go for $143.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 31.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #100 of 142 in the industry
Based on market cap of $38M.
FAQ
What kind of company is CVRX?
CVRX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CVRX?
The market cap of CVRX is approximately $38M, ranking 4,984 within its sector.
What is the 52-week high and low for CVRX?
CVRX has recorded a 52-week high of $11.30 and a low of $1.25.
